Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics
GET POWR RATINGS... FREE!
TRVI Stock Price Chart Interactive Chart >
TRVI Price/Volume Stats
|Current price||$3.73||52-week high||$3.86|
|Prev. close||$3.34||52-week low||$0.46|
|Day high||$3.86||Avg. volume||1,262,234|
|50-day MA||$2.42||Dividend yield||N/A|
|200-day MA||$1.53||Market Cap||144.30M|
Trevi Therapeutics, Inc. (TRVI) Company Bio
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
Most Popular Stories View All
TRVI Latest News Stream
|Loading, please wait...|
TRVI Latest Social Stream
View Full TRVI Social Stream
Latest TRVI News From Around the Web
Below are the latest news stories about Trevi Therapeutics Inc that investors may wish to consider to help them evaluate TRVI as an investment opportunity.
Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive interim analysis results from Phase 2 CANAL trial of Haduvio (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough. The company conducted a statistical analysis to assess the probability of success of CANAL based on the interim data. The interim analysis (N=26) was statistically significant on the primary efficacy endpoint, demonstrating a 52% placebo-adjusted reduction in the geometric mean perce
Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept. Further patient recruitment in the trial will stop based on the strength and consistency of the data.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that it has completed enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis (PN) and expects to report top-line data in the second quarter of 2022.
Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Stryker (SYK – Research Report) and Trevi Therapeutics (TRVI – Research Report). Stryker (SYK) In a report released today, Michael Matson from Needham maintained a Hold rating on Stryker. The company's shares closed last Thursday at $273.16, close to its 52-week high of $281.16. According to TipRanks.
TRVI Price Returns